Formulary updates

April 2018

  • Eclypse® Border dressings have been added to the formulary here. They have a higher acquisition cost in comparison to the non-border dressing and should be reserved for use in patients with heavily exuding wounds and following specialist Tissue Viability Nurse assessment of the wound.
  • Prontosan® irrigation fluid and gel products have been removed from the formulary and replaced by Octenilin® irrigation solution and gel which can be found here. Octenilin® is indicated for wound cleansing, moisturising and decontamination, and has a quicker acting time than Prontosan®. Octenilin® products are indicated for short term use only and are unsuitable for repeat prescription.
  • Zeroveen® emollient cream has been added to the formulary here. It is an emollient 2-in-1 moisturising cream and wash containing oatmeal, similar in formulation to Aveeno® cream but available at a lower acquisition cost.
  • BD Microfine+ 0.20mm/33G lancets have been discontinued. AgaMatrix Ultra-Thin 0.20mm/33G lancets have been added to the formulary here for use with the Wavesense Jazz blood glucose monitoring meter.
  • Salofalk® 500mg and 1g suppositories, Salofalk® 2g liquid enema and Salofalk® 1g foam enema have been added to the formulary here. They have been added to the formulary for the management of ulcerative colitis; these products are classified as 'Specialist' drugs to reflect the need for specialist input but continuation supplies may be prescribed in primary care.
  • Linezolid tablets and granules for oral suspension have been added to the formulary here. Linezolid has been added as a red drug with supportive prescribing notes.
  • Following public consultation; NHS England (NHSE) and NHS Clinical Commissioners (NHSCC) published guidance for CCGs on items which should not be routinely prescribed in primary care. Click here for more information. The following items have new guidance attached in the formulary:
  • Management of Hypertension: The formulary guidance has been reviewed and minor amendments made in line with NICE clinical guideline 127 (CG127), November 2016. The guidance can be found here.

March 2018

FreeStyle Libre interstitial glucose monitor has been added into the formulary for patients with type 1 diabetes mellitus who meet specific initiation and continuation criteria, following a commissioning decision from the Clinical Policy Committee. This device should be initiated by specialist endocrinologists only. Please see the formulary for further information.

Devon Formulary and Referral User Survey 2017

We would like to thank everyone who has taken part in the Devon Formulary and Referral user survey; the survey is now closed. Your responses will be analysed and the findings published, enabling the team to improve user experience and satisfaction, and inform the future direction of the formulary.

February 2018

  • Trimbow metered dose inhaler (MDI) (combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium) 87 micrograms/ 5 micrograms/ 9 micrograms has been added into the formulary, for use in patients aged 18 years and older with chronic obstructive pulmonary disease. Please see the formulary for further information.
  • Alprostadil intraurethral delivery systems 250 microgram, 500 microgram, and 1000 microgram have been added into the formulary, as an alternative treatment option to intracavernosal injection and topical aprostadil, for erectile dysfunction. Please see the formulary for further information.

December 2017

Activon® Tube 100% Medical Grade Manuka Honey has been added into the formulary as the preferred choice of honey-based topical application. Please see the formulary for further information. Medihoney 20g and 50g tubes have been removed from the formulary

ActivHeal® Silicone Foam Border Dressings have been added into the formulary as the preferred choice of silicone foam dressings. Please see the formulary for further information. Biatain Silicone Dressings have been removed from the formulary.

Sinemet tablets (62.5mg, 110mg, 275mg), Sinemet Plus tablets (125mg), Half Sinemet CR tablets (125mg), and Sinemet CR tablets (250mg) have all been removed as preferred brands from the formulary. Generic prescribing of co-careldopa is now recommended. See 4.9.1 Dopaminergic drugs used in Parkinson's disease

Neomag® 4mmol chewable tablets has been added into the formulary as a licensed preparation of magnesium glycerophosphate, for patients who cannot tolerate high sugar content in other formulary oral magnesium preparations. Please see the formulary for further information.

Sodium oxybate for narcolepsy with cataplexy has been reclassified from secondary care only to amber (specialist input) when used in line with the NEW Devon CCG Specialised Medicines Service prescribing guideline (funded from 1st January 2018). Please see the formulary for more information.

A NEW Devon CCG Specialised Medicines Service prescribing guideline (funded from 1st January 2018) is now available for the use of modafinil for excessive sleepiness associated with narcolepsy with or without cataplexy. The formulary entry has been updated accordingly.

Nausea and vomiting in pregnancy and hyperemesis gravidarum: new guidance in line with the Royal College of Obstetricians and Gynaecologists and NICE CKS has been added into the formulary. Please refer to the formulary for this new guidance.

 

Home > Formulary > Updates > Recent Updates

 

  • First line
  • Second line
  • Specialist
  • Hospital